BR0212019A - dosage forms, methods of treating pain, methods of preparing a dosage form and methods for preventing abuse of the dosage form - Google Patents

dosage forms, methods of treating pain, methods of preparing a dosage form and methods for preventing abuse of the dosage form

Info

Publication number
BR0212019A
BR0212019A BR0212019A BR0212019A BR0212019A BR 0212019 A BR0212019 A BR 0212019A BR 0212019 A BR0212019 A BR 0212019A BR 0212019 A BR0212019 A BR 0212019A BR 0212019 A BR0212019 A BR 0212019A
Authority
BR
Brazil
Prior art keywords
methods
dosage form
dosage
preparing
abuse
Prior art date
Application number
BR0212019A
Other languages
Portuguese (pt)
Inventor
Christopher Breder
Benjamin Oshlack
Richard Sackler
Curtis Wright
Robert Colucci
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US31053701P priority Critical
Priority to US31051501P priority
Priority to US31051601P priority
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Priority to PCT/US2002/024934 priority patent/WO2003013479A1/en
Publication of BR0212019A publication Critical patent/BR0212019A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

"FORMAS DE DOSAGEM, MéTODOS PARA O TRATAMENTO DA DOR, MéTODOS DE PREPARAçãO DE UMA FORMA DE DOSAGEM E MéTODOS PARA IMPEDIR O ABUSO DE UMA FORMA DE DOSAGEM". "DOSAGE FORMS, METHODS FOR TREATMENT OF PAIN, PREPARATION METHODS OF A DOSAGE FORM AND METHODS TO PREVENT ABUSE OF A DOSAGE FORM". Trata-se de métodos e composições para impedir o abuso de formas de dosagem de um analgésico de opióide e um antagonista de opióide que inclui pelo menos um agente aversivo em uma quantidade eficaz para impedir que um usuário em abuso administre uma forma alterada da dita forma de dosagem intravenosamente, intranasalmente, e/ou oralmente. It is methods and compositions for preventing abuse of dosage forms of an opioid analgesic and an opioid antagonist including at least one aversive agent in an amount effective to prevent a user from abuse administer an altered form of said medium dosage of intravenously, intranasally and / or orally.
BR0212019A 2001-08-06 2002-08-06 dosage forms, methods of treating pain, methods of preparing a dosage form and methods for preventing abuse of the dosage form BR0212019A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US31053701P true 2001-08-06 2001-08-06
US31051501P true 2001-08-06 2001-08-06
US31051601P true 2001-08-06 2001-08-06
PCT/US2002/024934 WO2003013479A1 (en) 2001-08-06 2002-08-06 Compositions and methods to prevent abuse of opioids

Publications (1)

Publication Number Publication Date
BR0212019A true BR0212019A (en) 2005-08-09

Family

ID=27405462

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212019A BR0212019A (en) 2001-08-06 2002-08-06 dosage forms, methods of treating pain, methods of preparing a dosage form and methods for preventing abuse of the dosage form

Country Status (10)

Country Link
EP (1) EP1414418A1 (en)
JP (1) JP2005501067A (en)
KR (1) KR20040060917A (en)
AU (1) AU2002319774B2 (en)
BR (1) BR0212019A (en)
CA (1) CA2456322A1 (en)
DE (1) DE20220910U1 (en)
HU (1) HU0401195A3 (en)
MX (1) MXPA04001208A (en)
WO (1) WO2003013479A1 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2266564T1 (en) 1997-12-22 2013-07-31 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU2002305559B2 (en) 2001-05-11 2008-04-03 Mundipharma Pty Limited Abuse-resistant controlled-release opioid dosage form
DE60230632D1 (en) * 2001-07-18 2009-02-12 Euro Celtique Sa Pharmaceutical combinations of oxycodone and naloxone
WO2003026743A2 (en) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
ES2627300T3 (en) 2002-04-05 2017-07-27 Mundipharma Pharmaceuticals S.L. Pharmaceutical preparation containing oxycodone and naloxone
KR101061351B1 (en) 2002-04-09 2011-08-31 플라멜 테크놀로지스 oral suspension of active ingredient microcapsules
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10250083A1 (en) * 2002-06-17 2003-12-24 Gruenenthal Gmbh Abuse-proofed dosage form
EP1894562B1 (en) * 2002-08-15 2010-12-15 Euro-Celtique S.A. Pharmaceutical compositions comprising an opioid antagonist
DE10250084A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
DE10250088A1 (en) * 2002-10-25 2004-05-06 Grünenthal GmbH Abuse-proofed dosage form
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1615625A4 (en) * 2003-04-21 2010-12-15 Euro Celtique Sa Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
CN101132772B (en) * 2005-01-28 2012-05-09 欧洲凯尔特公司 Alcohol resistant dosage forms
AT419836T (en) 2004-03-30 2009-01-15 Euro Celtique Sa Manipulation safe dosing form with an adsorben and an adverse medium
DE102004019916A1 (en) * 2004-04-21 2005-11-17 Grünenthal GmbH secured against misuse medicated plaster
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB0501638D0 (en) * 2005-01-28 2005-03-02 Euro Celtique Sa Particulates
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
FR2883179B1 (en) 2005-03-18 2009-04-17 Ethypharm Sa Coated tablet
FR2889810A1 (en) * 2005-05-24 2007-02-23 Flamel Technologies Sa Oral medicinal form, microparticular, anti-measurement
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
CN101370488B (en) 2005-11-22 2012-07-18 奥雷西根治疗公司 Compositions for increasing insulin sensitivity
EP1810714A1 (en) * 2006-01-19 2007-07-25 Holger Lars Hermann Use of a combination of heroin and naloxon for drug substitution
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
JP5478245B2 (en) * 2006-06-05 2014-04-23 オレキシジェン・セラピューティクス・インコーポレーテッド Naltrexone sustained release formulation
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
KR20140088619A (en) 2006-11-09 2014-07-10 오렉시젠 세러퓨틱스 인크. Unit dosage packages
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
US8420700B1 (en) * 2008-06-04 2013-04-16 James M. Bausch Tamper resistant lipid-based oral dosage form for sympathomimetic amines
US8273798B2 (en) * 2007-06-04 2012-09-25 Shear Kershman Laboratories Tamper resistant lipid-based oral dosage form for opioid agonists
EP2187873B1 (en) * 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
WO2009076764A1 (en) 2007-12-17 2009-06-25 Labopharm Inc. Misuse preventative, controlled release formulation
KR101616246B1 (en) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 Pharmaceutical dosage form
KR101690094B1 (en) 2008-05-09 2016-12-27 그뤼넨탈 게엠베하 Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
FR2938431B1 (en) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Novel composition based on gamma-hydroxybutyric acid
ES2509497T3 (en) 2008-12-16 2014-10-17 Paladin Labs Inc. Controlled release formulation to prevent misuse
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
AR077420A1 (en) 2009-07-22 2011-08-24 Gruenenthal Gmbh Dosage form resistant to manipulation for oxidation sensitive opioids
BR112012001547A2 (en) 2009-07-22 2016-03-08 Grünenthal GmbH hot melt extruded pharmaceutical dosage form
FR2949061B1 (en) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Floating microgranules
FR2949062B1 (en) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma New pharmaceutical formulations against measuring medicines
KR20120124423A (en) 2010-01-11 2012-11-13 오렉시젠 세러퓨틱스 인크. Methods of providing weight loss therapy in patients with major depression
NZ603497A (en) 2010-05-10 2015-02-27 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
CA2798885C (en) 2010-05-10 2014-11-18 Euro-Celtique S.A. Combination of active loaded granules with additional actives
MX2013002377A (en) 2010-09-02 2013-04-29 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt.
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
US9233073B2 (en) * 2010-12-23 2016-01-12 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
AU2012219322A1 (en) * 2011-02-17 2013-05-09 QRxPharma Ltd. Technology for preventing abuse of solid dosage forms
ES2655900T3 (en) 2011-07-29 2018-02-22 Grünenthal GmbH Tamper-proof tablet that provides immediate release of a medication
AU2013225106B2 (en) 2012-02-28 2017-11-02 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (en) 2012-04-18 2018-12-31 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
ES2436344B1 (en) * 2012-05-29 2014-08-07 Onedose Pharma, S.L. Pharmaceutical composition of diacetylmorphine and naloxone for oral administration
AU2013271622B2 (en) 2012-06-06 2018-03-01 Nalpropion Pharmaceuticals, Inc. Methods of treating overweight and obesity
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2907428A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
JP6466417B2 (en) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング A tamper-resistant dosage form with a bimodal release profile
EP3024461A1 (en) 2013-07-23 2016-06-01 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
DE112014005175T5 (en) 2013-11-13 2016-07-21 Euro-Celtique S.A. Hydromorphone and naloxone for the treatment of pain and opioid bowel dysfunction syndrome
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (en) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Multiparticulates protected against ethanol overdose
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
BR112017021475A2 (en) 2015-04-24 2018-07-10 Gruenenthal Gmbh tamper-resistant dosage form with immediate release and resistance to solvent extraction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations

Also Published As

Publication number Publication date
MXPA04001208A (en) 2004-07-08
KR20040060917A (en) 2004-07-06
DE20220910U1 (en) 2004-08-05
AU2002319774B2 (en) 2005-04-21
HU0401195A3 (en) 2006-11-28
JP2005501067A (en) 2005-01-13
HU0401195A2 (en) 2004-10-28
WO2003013479A1 (en) 2003-02-20
EP1414418A1 (en) 2004-05-06
CA2456322A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
CN1279055C (en) Antibody that immunospecifically bind to BLYS
JP4817495B2 (en) Pain control with exogenous cannabinoids
KR930007450A (en) Tramadol and non-steroidal anti-inflammatory agent compositions containing
NO325177B1 (en) Pyrimidine compounds, process feed for the preparation thereof, pharmaceutical compositions comprising such, such compounds as medicaments and their use in such manufacture of a medicament for the treatment of disease
BR0005266A (en) Compounds for the treatment of female sexual disfução
BR0014512A (en) Topical treatment for streptococcal infections
BR0111186A (en) Use of celecoxib composition for rapid relief of pain
TR200201317T2 (en) Synergistic.
RS52922B (en) Compositions and uses for treating multiple sclerosis
BR9911046A (en) Tricyclic antidepressants for local analgesia
AR032132A1 (en) pharmaceutical composition comprising a combination of a compound of tramadol and an anticonvulsant drug combination and use for preparing a medicament
BR0116575A (en) Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
BR0200283A (en) Pharmaceutical compositions for the treatment of CNS disorders and other disorders
NO950774L (en) A method for inhibiting bone loss and lowering serum cholesterol
EE200100176A (en) The use of fentanyl in the preparation of a pharmaceutical composition which is intended for the treatment of acute pain, and a pharmaceutical composition
BR0209147A (en) Combination therapy using anti-EGFR antibodies and anti-hormonal agents
SA98190557A (en) N-aroylphenylalanine derivatives.
NO20075682L (en) Compositions comprising an orally active 1,2,4-oxadiazol for nonsense mutation suppression therapy
NO20025627D0 (en) Methods and compositions for treating hepatitis C virus
BR0116505A (en) A compound or pharmaceutically acceptable salt thereof, pharmaceutical compositions, method for treating or preventing diseases or disorders where an antagonist of a human orexin receptor is required, and process for the manufacture of pharmaceutical compositions for the treatment of disorders associated with the role of orexin, especially obesity and sleep disorders
TR199901417T2 (en) new compounds having analgesic effect.
NO334316B1 (en) Use of safinamide in combination with levodopa / PDI, for the preparation of medicaments for the treatment of Parkinson's disease
CY1111967T1 (en) DOSAGE FORM containing oxycodone and naloxone
NO334233B1 (en) A pharmaceutical composition comprising milnacipran for the treatment of irritable bowel syndrome
SA2709B1 (en) Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired